Page last updated: 2024-10-15

pyrrhocoricin protein, pyrrhocoris apterus

Description

pyrrhocoricin protein, Pyrrhocoris apterus: a 20-residue proline-rich peptide carrying an O-glycosylated substitution; from the sap-sucking bug Pyrrhocoris apterus; active against Gram-negative bacteria; amino acid sequence given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16131340
CHEMBL ID405360
MeSH IDM0232261

Synonyms (4)

Synonym
CHEMBL405360
pyrrhocoricin, pyrrhocoris apterus
pyrrhocoricin protein, pyrrhocoris apterus
156548-23-1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID492540Binding affinity to Escherichia coli DNAK substrate binding domain2010Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
Heat shock protein 70 (hsp70) as an emerging drug target.
AID322746Toxicity against human erythrocytes assessed as hemolytic activity2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Fatty acyl benzamido antibacterials based on inhibition of DnaK-catalyzed protein folding.
AID322747Inhibition of Escherichia coli MC4100 DnaK assessed as effect on luciferase refolding2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Fatty acyl benzamido antibacterials based on inhibition of DnaK-catalyzed protein folding.
AID322736Antimicrobial activity against Escherichia coli MC4100 at 42 degC2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Fatty acyl benzamido antibacterials based on inhibition of DnaK-catalyzed protein folding.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (9.09)18.2507
2000's14 (63.64)29.6817
2010's6 (27.27)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.35%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]